LIFE - aTyr Pharma granted U.S. patent covering use of ATYR1923 in lung inflammation

aTyr Pharma (NASDAQ:LIFE) announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering methods for the use of histidyl-tRNA synthetase Fc fusion proteins for reducing inflammatory response in the lung. The patent covers the use of the company’s lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung. ATYR1923 is a Fc fusion protein based on the N terminal fragment of histidyl-tRNA synthetase that is currently in clinical development for the treatment of pulmonary sarcoidosis and is being evaluated in other inflammatory lung diseases. Shares up more than 2% post market.

For further details see:

aTyr Pharma granted U.S. patent covering use of ATYR1923 in lung inflammation